Effects of diagnosis by newborn screening for cystic fibrosis on weight and length in the first year of life

Daniel H. Leung*, Sonya L. Heltshe, Drucy Borowitz, Daniel Gelfond, Margaret Kloster, James E. Heubi, Michael Stalvey, Bonnie W. Ramsey, A. Stecenko, M. Schechter, E. Hunter, W. Hoover, H. Hathorne, K. Brand, A. Filbrun, M. Linn, D. Borowitz, N. Caci, B. McWilliams, I. BrazilJ. Heubi, M. Bushman, S. McColley, A. Bowen, K. McCoy, K. Sakellaris, P. Sharma, C. Cannon, A. Hebert, S. Sagel, M. Anthony, M. Dyson, H. Urbanek, S. Millard, C. Gile, G. Graff, L. Allwein, P. Hiatt, N. Schaap, N. Krupp, L. Bendy, R. Ahrens, M. Teresi, A. Berlinski, L. L. Ramsey, J. McNamara, M. Johnson, R. Brown, P. Berry, N. Mehdi, Baby Observational and Nutrition Study (BONUS) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

69 Scopus citations


IMPORTANCE: Since the implementation of universal newborn screening (NBS) for cystic fibrosis (CF), the timing and magnitude of growth deficiency or its association with correlates of disease among infants with CF who underwent NBS has not been well described. OBJECTIVE: To examine incremental weight gain, linear growth, and clinical features in the first year of life among infants with CF who underwent NBS. DESIGN, SETTING, AND PARTICIPANTS: The Baby Observational and Nutrition Study (BONUS), a multicenter, longitudinal, observational cohort study, was conducted during regular CF clinic visits in the first 12 months of life at 28 US Cystic Fibrosis Foundation-accredited Care Centers from January 7, 2012, through May 31, 2015. Participants included 231 infants younger than 3.5 months who underwent NBS and had confirmed CF, with a gestational age of at least 35 weeks, birth weight of at least 2.5 kg, and toleration of full oral feeds. Of these, 222 infants (96.1%) had follow-up beyond 6 months of age and 215 (93.1%) completed 12 months of follow-up. EXPOSURE: Cystic fibrosis. MAIN OUTCOME AND MEASURES: Attained weight and length for age and World Health Organization normative z scores at ages 1 to 6 and 8, 10, and 12 months (defined a priori). RESULTS: Of the 231 infants enrolled, 110 infants (47.6%) were female and 121 (52.4%) were male, with a mean (SD) age of 2.58 (0.69) months. BONUS infants had lower than mean birth weights (mean z score, -0.15; 95%CI, -0.27 to -0.04) and higher birth lengths (mean z score, 0.44; 95%CI, 0.26 to 0.62). They achieved normal weight by 12 months, a significant improvement over a prescreening cohort of newborns with CF from 20 years before the contemporary cohort (mean z score increase, 0.57; 95%CI, 0.37-0.77). However, length was lower than the mean at 12 months (mean z score, -0.56; 95%CI, -0.70 to -0.42). Only 30 infants (13.6%) were at less than the 10th percentile of weight for age, whereas 53 (23.9%) were at less than the 10th percentile of length for age at more than half their visits. Male sex, pancreatic insufficiency, meconium ileus, histamine blocker use, and respiratory Pseudomonas aeruginosa infection were associated with lower weight or length during the first year. Insulinlike growth factor 1 levels were significantly lower among low-length infants. Persistently low-weight infants consumed significantly more calories, and weight and length z scores were negatively correlated with caloric intake. CONCLUSIONS AND RELEVANCE: Since initiation of universal NBS for CF, significant improvement has occurred in nutritional status, with normalization of weight in the first year of life. However, length stunting remains common.

Original languageEnglish (US)
Pages (from-to)546-554
Number of pages9
JournalJAMA Pediatrics
Issue number6
StatePublished - Jun 2017

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Effects of diagnosis by newborn screening for cystic fibrosis on weight and length in the first year of life'. Together they form a unique fingerprint.

Cite this